ConditionChronic Limb-Threatening Ischemia
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssiut University
About this trial
Chronic limb-threatening ischemia (CLTI) is the most severe form of peripheral artery disease and remains a major health problem. Although the angiosome concept was introduced to guide revascularization by restoring direct blood flow to the affected tissue, its usefulness is limited by anatomical variations, collateral circulation, and wounds involving multiple territories. The emerging "woundsome" concept focuses instead on improving arterial perfusion directly to the wound area, recognizing that both direct revascularization and
Eligibility criteria
Qualifiers
None
Disqualifiers
Patients with unsalvageable limbs
Patients with acute limb ischemia (ALI)
Patients with contraindications to contrast medium
Patients with aortoiliac or femoropopliteal occlusive disease
Trial design
Treatments tested in this trial
- Revascularization by Percutaneous Transluminal Angioplasty
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov